Genovate Biotechnology Co (ROCO:4130) Stock Based Compensation: NT$10.7 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4130 Genovate Biotechnology Co Ltd ROCO:4130
67 GF Score
Price NT$26.70
GF Value NT$19.99
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Genovate Biotechnology Co Stock Based Compensation?

Genovate Biotechnology Co ROCO:4130 67 Stock Based Compensation is NT$10.7 Mil as of Mar. 2026. GuruFocus rates ROCO:4130 with a GF Score™ of 67/100 and a GF Value™ of NT$19.99 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Genovate Biotechnology Co's Stock Based Compensation for the three months ended in Mar. 2026 was NT$10.7 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was NT$10.7 Mil.

Genovate Biotechnology Co Stock Based Compensation Related Terms

Genovate Biotechnology Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Genovate Biotechnology Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovate Biotechnology Co Stock Based Compensation Chart

Genovate Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 11.70 0.00 0.00 0.00

Genovate Biotechnology Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 10.69
ROCO:4130
67GF Score
Genovate Biotechnology Co Ltd ROCO:4130
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genovate Biotechnology Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$10.7 Mil.

What does a Stock Based Compensation of NT$10.7 Mil mean?
Genovate Biotechnology Co (ROCO:4130) has a Stock Based Compensation of NT$10.7 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Genovate Biotechnology Co and its competitors.
Is Genovate Biotechnology Co's Stock Based Compensation too high?
Genovate Biotechnology Co's current Stock Based Compensation is NT$10.7 Mil. Overall, Genovate Biotechnology Co has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's Stock Based Compensation compare to VRTX and REGN?
Genovate Biotechnology Co's Stock Based Compensation of NT$10.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Genovate Biotechnology Co and its competitors. Genovate Biotechnology Co's current Stock Based Compensation is NT$10.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$19.99, compared to a current price of NT$26.70 — trading 33.6% above its estimated fair value. The current Stock Based Compensation is NT$10.7 Mil. Genovate Biotechnology Co's overall GF Score™ is 67/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current Stock Based Compensation is NT$10.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?

Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued. The current stock price of NT$26.70 is trading 33.6% above its estimated GF Value™ of NT$19.99. GuruFocus considers Genovate Biotechnology Co to be Significantly Overvalued.

Key valuation signals for ROCO:4130:

  • Stock Based Compensation: NT$10.7 Mil
  • GF Value™: NT$19.99 vs. price of NT$26.70 (33.6% above fair value)
  • GF Score™: 67/100 with 1 warning sign

No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genovate Biotechnology Co Business Description

Address No.1, First Industrial Road, Hsin-Chu Expanded Park, Hukou Township, Guangdong Province, Hsin-Chu county, Hsin-Chu, TWN, 303036
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
67GF Score

Get the complete analysis for ROCO:4130

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.70
Price
NT$19.99
GF Value